The CRISPR community is facing a tsunami of data but a dearth of computational tools required for their analyses. By empowering the researcher, Latch is helping remove a significant bottleneck that is currently slowing down the CRISPR research cycle, enabling the discovery of new therapies.
Investors 2
| Date | Name | Website |
| 07.10.2021 | Lux Capita... | luxcapital... |
| - | Axial VC | axialvc.co... |
Mentions in press and media 1
| Date | Title | Description | Category | Author | Source |
| - | Biocomputi... | Latch Bio — a company building... | - | - | pulse2.com... |